These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Analysis of relapse by inflammatory Rasch-built overall disability scale status in the PATH study of subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy. Merkies ISJ; van Schaik IN; Bril V; Hartung HP; Lewis RA; Sobue G; Lawo JP; Mielke O; Cornblath DR; J Peripher Nerv Syst; 2022 Jun; 27(2):159-165. PubMed ID: 35266243 [TBL] [Abstract][Full Text] [Related]
6. Patient-reported outcomes with subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: the PATH study. Hartung HP; Mallick R; Bril V; Lewis RA; Sobue G; Lawo JP; Mielke O; Durn BL; Cornblath DR; Merkies ISJ; van Schaik IN; Eur J Neurol; 2020 Jan; 27(1):196-203. PubMed ID: 31400231 [TBL] [Abstract][Full Text] [Related]
7. IgPro20, the Polyneuropathy and Treatment with Hizentra Berger M; Harbo T; Cornblath DR; Mielke O Immunotherapy; 2018 Aug; 10(11):919-933. PubMed ID: 29764262 [TBL] [Abstract][Full Text] [Related]
8. Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre-randomization phase of the Polyneuropathy And Treatment with Hizentra study. Mielke O; Bril V; Cornblath DR; Lawo JP; van Geloven N; Hartung HP; Lewis RA; Merkies ISJ; Sobue G; Durn B; Shebl A; van Schaik IN; J Peripher Nerv Syst; 2019 Mar; 24(1):72-79. PubMed ID: 30672067 [TBL] [Abstract][Full Text] [Related]
9. Electrophysiological predictors of response to subcutaneous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy. Alcantara M; Hartung HP; Lawo JP; Durn BL; Mielke O; Bril V Clin Neurophysiol; 2021 Sep; 132(9):2184-2190. PubMed ID: 34293528 [TBL] [Abstract][Full Text] [Related]
10. Impact of subcutaneous immunoglobulin on quality of life in patients with chronic inflammatory demyelinating polyneuropathy previously treated with intravenous immunoglobulin. Vu T; Anthony N; Alsina R; Harvey B; Schleutker A; Farias J; Dang S; Suresh N; Gooch C Muscle Nerve; 2021 Sep; 64(3):351-357. PubMed ID: 34076265 [TBL] [Abstract][Full Text] [Related]
11. Electrophysiological testing in chronic inflammatory demyelinating polyneuropathy patients treated with subcutaneous immunoglobulin: The Polyneuropathy And Treatment with Hizentra (PATH) study. Bril V; Hartung HP; Lawo JP; Durn BL; Mielke O Clin Neurophysiol; 2021 Jan; 132(1):226-231. PubMed ID: 33039291 [TBL] [Abstract][Full Text] [Related]
12. Hyaluronidase-facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: The ADVANCE-CIDP 1 randomized controlled trial. Bril V; Hadden RDM; Brannagan TH; Bar M; Chroni E; Rejdak K; Rivero A; Andersen H; Latov N; Levine T; Pasnoor M; Sacconi S; Souayah N; Anderson-Smits C; Duff K; Greco E; Hasan S; Li Z; Yel L; Ay H J Peripher Nerv Syst; 2023 Sep; 28(3):436-449. PubMed ID: 37314318 [TBL] [Abstract][Full Text] [Related]
13. Long-term treatment with subcutaneous immunoglobulin in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a follow-up period up to 7 years. Gentile L; Mazzeo A; Russo M; Arimatea I; Vita G; Toscano A Sci Rep; 2020 May; 10(1):7910. PubMed ID: 32404895 [TBL] [Abstract][Full Text] [Related]
14. Pharmacometric analysis linking immunoglobulin exposure to clinical efficacy outcomes in chronic inflammatory demyelinating polyneuropathy. Tortorici MA; Yuraszeck T; Cornblath D; Bril V; Hartung HP; Sobue G; Lewis RA; Merkies ISJ; Lawo JP; Praus M; Durn BL; Mielke O; Ma X; Jauslin P; Pfister M; van Schaik IN; CPT Pharmacometrics Syst Pharmacol; 2021 Aug; 10(8):839-850. PubMed ID: 34085779 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency diseases. Kanegane H; Imai K; Yamada M; Takada H; Ariga T; Bexon M; Rojavin M; Hu W; Kobayashi M; Lawo JP; Nonoyama S; Hara T; Miyawaki T J Clin Immunol; 2014 Feb; 34(2):204-11. PubMed ID: 24504846 [TBL] [Abstract][Full Text] [Related]
16. Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial. Allen JA; Lin J; Basta I; Dysgaard T; Eggers C; Guptill JT; Gwathmey KG; Hewamadduma C; Hofman E; Hussain YM; Kuwabara S; Le Masson G; Leypoldt F; Chang T; Lipowska M; Lowe M; Lauria G; Querol L; Simu MA; Suresh N; Tse A; Ulrichts P; Van Hoorick B; Yamasaki R; Lewis RA; van Doorn PA; Lancet Neurol; 2024 Oct; 23(10):1013-1024. PubMed ID: 39304241 [TBL] [Abstract][Full Text] [Related]
17. Safety and Tolerability of Subcutaneous IgPro20 at High Infusion Parameters in Patients with Primary Immunodeficiency: Findings from the Pump-Assisted Administration Cohorts of the HILO Study. Anderson JT; Bonagura VR; Cowan J; Hsu C; Mustafa SS; Patel NC; Routes JM; Sriaroon P; Vinh DC; Hofmann JH; Praus M; Rojavin MA J Clin Immunol; 2021 Feb; 41(2):458-469. PubMed ID: 33409867 [TBL] [Abstract][Full Text] [Related]